B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece.
OBJECTIVE
Leptin and adiponectin are two well-studied adipokines in relation to malignancies. In this study, we examined the association between leptin/adiponectin and risk of B-cell chronic lymphocytic leukemia (B-CLL), as well as the relationships between adipokines and several established prognostic factors of B-CLL.


METHODS
Ninety-five patients with incident B-CLL and 95 hospital controls matched on age and gender were studied between 2001 and 2007, and blood samples were collected. Leptin, total and high molecular weight adiponectin, and prognostic markers of B-CLL were determined.


RESULTS
Cases had a higher body mass index (BMI) than controls (p = 0.01) and lower levels of leptin (p < 0.01). Significantly more cases than controls presented a family history of lymphohematopoietic cancer (LHC) (p = 0.01). Higher serum leptin levels were associated with lower risk of B-CLL adjusting for age, gender, family history of LHC, BMI and serum adiponectin; the multivariate odds ratio comparing highest to lowest tertile was 0.05 (95% CI 0.01-0.29, p trend < 0.001); Adiponectin was not significantly different between cases and controls.


CONCLUSIONS
Leptin was found to be inversely associated with risk of CLL but in contrast to prior studies of CLL and hematologic malignancies, this study found no significant association between CLL and adiponectin.
Dalamaga
Maria
M
Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Athens, Greece.
Crotty
Bradley H
BH
Fargnoli
Jessica
J
Papadavid
Evangelia
E
Lekka
Antigoni
A
Triantafilli
Maria
M
Karmaniolas
Konstantinos
K
Migdalis
Ilias
I
Dionyssiou-Asteriou
Amalia
A
Mantzoros
Christos S
CS
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D005260:Female; D006115:Greece; D006801:Humans; D020738:Leptin / Q000097:blood*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011863:Radioimmunoassay; D012307:Risk Factors
D052242:Adiponectin; D014408:Biomarkers, Tumor; D020738:Leptin
J Leukoc Biol. 2000 Oct;68(4):437-46
11037963
Exp Oncol. 2006 Sep;28(3):241-4
17080020
Egypt J Immunol. 2003;10(1):57-66
15719623
Int J Hematol. 2006 Apr;83(3):254-8
16720558
Haematologica. 2002 Jun;87(6):584-95
12031914
Br J Cancer. 2006 Jan 16;94(1):156-60
16404369
J Biol Chem. 2003 Oct 10;278(41):40352-63
12878598
Cancer Res. 2006 Dec 1;66(23):11462-70
17145894
J Exp Clin Cancer Res. 2006 Dec;25(4):537-41
17310845
Endocr Relat Cancer. 2007 Sep;14(3):713-20
17914101
Br J Cancer. 2006 May 8;94(9):1221-5
16570048
Nat Med. 2001 Aug;7(8):941-6
11479627
Br J Haematol. 1998 Aug;102(3):740-5
9722301
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14564-8
8962092
Int J Cancer. 2008 Mar 15;122(6):1418-21
18027857
Leuk Res. 2003 Oct;27(10):871-6
12860003
J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23
8784108
Ann Oncol. 1999 Dec;10(12):1419-32
10643532
Eur J Cancer. 2008 Aug;44(12):1744-53
18515085
Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
16859394
Int J Hematol. 2008 Nov;88(4):374-380
18818986
Blood. 2000 Sep 1;96(5):1723-32
10961870
J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
17192291
Oncology. 2007;73(1-2):26-32
18337619
Am J Epidemiol. 2002 Sep 15;156(6):527-35
12226000
Nature. 2003 Jun 12;423(6941):762-9
12802337
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6793-9
16203766
Cancer. 1981 Jul 1;48(1):198-206
7237385
Endocr Rev. 2005 May;26(3):439-51
15897298
Am J Clin Nutr. 2007 Sep;86(3):s858-66
18265479
J Biol Chem. 2004 Jul 16;279(29):30817-22
15123605
Leuk Lymphoma. 2000 Feb;36(5-6):457-61
10784389
Cell Res. 2007 Apr;17(4):280-2
17404599
Blood. 1996 Jun 15;87(12):4990-7
8652811
Dig Dis Sci. 2008 Mar;53(3):597-605
17763959
Cancer Causes Control. 2001 Jan;12(1):13-21
11227921
J Immunol. 2007 Mar 15;178(6):3511-20
17339446
Int J Hematol. 2002 Dec;76(5):446-52
12512839
Bone. 2004 Oct;35(4):842-9
15454091
Physiol Behav. 2006 Jun 30;88(3):249-56
16782141
Cancer Causes Control. 2009 Mar;20(2):193-9
18814045
Blood. 1999 Mar 1;93(5):1668-76
10029596
Endocrinology. 2005 Feb;146(2):790-6
15528304
Int J Cancer. 2007 Oct 1;121(7):1564-70
17443495
Curr Treat Options Oncol. 2002 Jun;3(3):225-31
12057068
J Immunol. 2003 Nov 15;171(10):5091-9
14607907
Curr Biol. 1996 Sep 1;6(9):1170-80
8805376
N Engl J Med. 1996 Feb 1;334(5):292-5
8532024
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81
14983034
Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87
15196232
J Clin Invest. 2003 May;111(9):1409-21
12727933
Br J Haematol. 1997 Sep;98(4):934-9
9326192
Horm Metab Res. 2007 Jan;39(1):9-13
17226107